Abstract:Multiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory- demyelinating disorder of the central nervous system (CNS). It usually begins in young adulthood, mainly between the second and fourth decades of life. Usually, the clinical course is characterized by the involvement of multiple CNS functional systems and by different, often overlapping phenotypes. In the last decades, remarkable results have been achieved in the treatment of MS, particularly in the relapsing- remitting (RRMS) form, thus improving the long-term outcome for many patients. As deeper knowledge of MS pathogenesis and respective molecular targets keeps growing, nowadays, several lines of disease-modifying treatments (DMT) are available, an impressive change compared to the relative poverty of options available in the past. Current MS management by DMTs is aimed at reducing relapse frequency, ameliorating symptoms, and preventing clinical disability and progression. Notwithstanding the relevant increase in pharmacological options for the management of RRMS, research is now increasingly pointing to identify new molecules with high efficacy, particularly in progressive forms. Hence, future efforts should be concentrated on achieving a more extensive, if not exhaustive, understanding of the pathogenetic mechanisms underlying this phase of the disease in order to characterize novel molecules for therapeutic intervention. The purpose of this review is to provide a compact overview of the numerous currently approved treatments and future innovative approaches, including neuroprotective treatments as anti-LINGO-1 monoclonal antibody and cell therapies, for effective and safe management of MS, potentially leading to a cure for this disease.

Current and emerging therapies in multiple sclerosis: a systematic review

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis

Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches

Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action

Newer agents in the treatment of multiple sclerosis

Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects

A review of possible therapies for multiple sclerosis

Multiple sclerosis: therapeutic update

Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis

Multiple sclerosis treatments a review of current biomedical engineering approaches

Immunomodulatory Therapies of Multiple Sclerosis

Multiple sclerosis: pathogenesis and treatment

Early Aggressive Treatment Approaches for Multiple Sclerosis

Multiple sclerosis. Recent modalities of treatment

Progressive multiple sclerosis: latest therapeutic developments and future directions

[Treatments for multiple sclerosis: update]

[Current therapy of multiple sclerosis]

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients

Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists